# Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

> **NCT01058005** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 84 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** BG00002 (natalizumab)
- **DRUG:** interferon beta-1a
- **DRUG:** glatiramer acetate

## Key facts

- **NCT ID:** NCT01058005
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study.
- **Last updated:** 2014-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01058005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01058005, "Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01058005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*